Food and Drug Administration, Dockets Management Branch, 5630 Fishers Lane - Room 1061- HFA-305, Rockville, MD, 20852; 301-827-6860; Fax 301-827-6870; TTY/TDD Users 1-800-735-2258 - [E-mail Us]

DOCKETS ENTERED on 12/24/02

TABLE OF CONTENTS

Hyper links are part of the Docket  title - not all dockets/documents are linked

NOTE:  Documents received by the Dockets Management Branch "MAY" be posted on the Internet. PLEASE DO NOT include personal identifying information, i.e. date of birth, social security number, etc., in your correspondence.

[FDA DOCKETS PAGE] [FDA HOME PAGE]  [ ITEM CODES ]

 
75N-183H Health-Care Antiseptic Drug Products for OTC Human Use *
76N-052N OTC Nasal Decongestants *
00N-1571 Enrofloxacin for Poultry: Opportunity for Hearing *
02D-0266 Guidance preventive measures to reduce risk of (CJD) *
02D-0389 Nonclinical Studies for Development of Pharmaceutical Excipi *
02N-0273 Animal Proteins Prohibited in Ruminant Feed *
02N-0290 Proposal to Derbar Neelam Bhutani;Notice of Opportunity for *
02N-0291 Proposal to Debar Baldev Raj Bhutani;Notice of Opportunity *
02N-0417 Applications for FDA Approval to Market a New Drug *
02N-0510 Proposal to Debar Thomas M. Rodgers, Jr. *
02N-0511 Proposal to Debar Thomas R. Theodore;Notice of Opportunity *

75N-183H Health-Care Antiseptic Drug Products for OTC Human Use

LET 34 Aleavis International,Inc. Vol#: 60

76N-052N OTC Nasal Decongestants

SUP 6 Bayer Corporation Vol#: 84

96N-0135 Protein Derived from Ruminants Prohibited in Ruminant Feed

REF 4 OMB Review on 1/3/97 Vol#: 88

98P-0151 Introduction Of Downed Cattle Into The Food Supply

EMC 3020 Ryna Appleton Segal Vol#: 265

00N-1571 Enrofloxacin for Poultry: Opportunity for Hearing

CR 2 Bayer Corporation Vol#: 353

CS 25 HFA-305 Vol#: 353

MO 31 Center for Veterinary Medicine Vol#: 353

MO 32 Bayer Corporation Vol#: 353

OR 27 HF-3 Vol#: 353

01P-0230 Domestic Marketing & Importation of Transgenic Fish

C 1293 Harold M. Thomas Esq. Vol#: 226

EMC 2622 Lauren Gascoigne Vol#: 228

EMC 2623 Heather Dunlop Vol#: 228

EMC 2624 Joshua Chiles Vol#: 228

EMC 2625 Beth Foss Vol#: 228

EMC 2626 Burnis Tuck Vol#: 228

EMC 2627 Barbara E. Raimond Vol#: 228

EMC 2628 Jamie Drumlin Vol#: 228

EMC 2629 Samantha Issleb Vol#: 228

EMC 2630 Beatrice Einhorn Vol#: 228

EMC 2631 Micah Sanford Vol#: 228

EMC 2632 Robert Nowotny Vol#: 228

EMC 2633 Sharon Wilner Vol#: 228

EMC 2634 Patricia Weberman Vol#: 228

EMC 2635 Kelly Chiles Vol#: 228

02D-0266 Guidance preventive measures to reduce risk of (CJD)

C 11 Eye-Bank for Sight Restoration, Inc. Vol#: 1

C 12 Eye Bank Assn of America (EBAA) Vol#: 1

C 13 America Assn of Tissue Banks (AATB) Vol#: 1

EMC 16 American Academy of Ophthalmology (AAO) Vol#: 1

EMC 17 Eye Bank Assn of America (EBAA) Vol#: 1

EMC 18 American Asn of Tissue Banks (AATB) Vol#: 1

EXT 1 King & Spalding Vol#: 1

02D-0389 Nonclinical Studies for Development of Pharmaceutical Excipi

C 3 GlaxoSmithKline Vol#: 1

02M-0527 PMA for EXCLUDER Bifurcated Endoprosthesis, P020004

AAV 1 W L Gore & Associated, Inc. Vol#: 1

02N-0273 Animal Proteins Prohibited in Ruminant Feed

C 1 American Proteins, Inc. Vol#: 1

02N-0290 Proposal to Derbar Neelam Bhutani;Notice of Opportunity for

NPH 1 HFD-1 Vol#: 1

02N-0291 Proposal to Debar Baldev Raj Bhutani;Notice of Opportunity

NPH 1 HFD-1 Vol#: 1

02N-0417 Applications for FDA Approval to Market a New Drug

C 22 Teva Pharmaceuticals, Inc. Vol#: 1

C 23 aiiPharma, Inc. Vol#: 1

C 24 Fish & Richardson, PC Vol#: 1

C 25 RxHealthValue Vol#: 1

C 26 Organon, Inc. Vol#: 1

C 27 PhRMA Vol#: 1

EMC 5 Apotex Corp. Vol#: 1

EMC 6 American Pharmaceutical Assn (APhA) Vol#: 1

EMC 7 Kos Pharmaceuticals, Inc. Vol#: 1

EMC 8 Washington Legal Foundation Vol#: 1

02N-0510 Proposal to Debar Thomas M. Rodgers, Jr.

NPH 1 HFM-1 Vol#: 1

02N-0511 Proposal to Debar Thomas R. Theodore;Notice of Opportunity

NPH 1 HFM-1 Vol#: 1